K. Seaton

发表

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials

Lindsay N. Carpp, J. Mascola, J. Schiffer, 2018, Human vaccines & immunotherapeutics.

Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection

B. Haynes, Myron S. Cohen, K. Soderberg, 2011, AIDS.

Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination

Gary J. Nabel, Guido Ferrari, Youyi Fong, 2014, Science Translational Medicine.

Computational analysis of antibody dynamics identifies recent HIV-1 infection.

H. Liao, B. Haynes, M. Robb, 2017, JCI insight.

Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies

T. Kepler, S. Hammer, H. Liao, 2015, Science.

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

Nico Pfeifer, Michael S. Seaman, Florian Klein, 2018, Nature.

Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity

Rutilio H. Clark, Randal R Ketchem, J. Shaver, 2020, Journal of pharmaceutical sciences.

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study

Allan C. deCamp, J. Weiner, M. Nussenzweig, 2019, PloS one.

Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1

H. Liao, G. Ferrari, Gerald Tegha, 2015, Journal of Virology.

IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model

Rachel L. Spreng, Lindsay C. Dahora, S. Alam, 2019, Front. Immunol..

SIMON: Open-Source Knowledge Discovery Platform

Mark M. Davis, Rachel L. Spreng, Lindsay C. Dahora, 2020, bioRxiv.

HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques

T. Kepler, Laura L. Sutherland, B. Haynes, 2017, Journal of Virology.

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans

Lindsay N. Carpp, L. Zhao, N. Frahm, 2020, PloS one.

Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature

S. Buchbinder, J. Thakar, P. Goepfert, 2020, Scientific Reports.

Speci ﬁ city and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modi ﬁ ed Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles

S. Hammer, B. Moss, S. Buchbinder, 2014 .

Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens

Lindsay N. Carpp, S. Buchbinder, M. McElrath, 2022, EBioMedicine.

Innate Activation of MDC and NK Cells in High-Risk HIV-1–Exposed Seronegative IV-Drug Users Who Share Needles When Compared With Low-Risk Nonsharing IV-Drug User Controls

L. Montaner, D. Metzger, G. Tomaras, 2015, Journal of acquired immune deficiency syndromes.

Rectal and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge.

S. Hammer, M. McElrath, I. Frank, 2021, The Journal of clinical investigation.

Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge

S. Hammer, M. McElrath, I. Frank, 2021 .

Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines

J. Kublin, A. Fiore-Gartland, Xiaoying Shen, 2022, Frontiers in Immunology.

Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel

D. Lauffenburger, M. Altfeld, L. Morris, 2015, Mucosal Immunology.

Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

Nico Pfeifer, Florian Klein, Michel C Nussenzweig, 2018, Nature Medicine.

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

J. Mascola, D. Montefiori, R. Bailer, 2017, PLoS medicine.

T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response.

M. Ostrowski, M. Betts, M. Robb, 2017, JCI insight.

HIV-1 Negative Female Sex Workers Sustain High Cervical IFNε, Low Immune Activation and Low Expression of HIV-1 Required Host Genes

L. Montaner, K. Linn, Qingsheng Li, 2015, Mucosal Immunology.

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

Lindsay N. Carpp, Allan C. deCamp, J. Mullins, 2022, Nature Medicine.

Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk.

Lindsay N. Carpp, J. Kublin, M. McElrath, 2022, The Journal of infectious diseases.

Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens

S. Alam, A. Hill, S. Dennison, 2018, The Journal of Immunology.

Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children

M. Hughes, D. Kuritzkes, M. Lichterfeld, 2022, Journal of acquired immune deficiency syndromes.

Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection

Rachel L. Spreng, Sarah V. Mudrak, E. Jongert, 2021, npj Vaccines.

The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination

Muhammad Bilal Latif, B. Haynes, R. Koup, 2021, Nature Immunology.

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

M. Nussenzweig, A. West, E. Thomas, 2018, Nature.

OP 7.2 – 00035 Impact of 10-1074LS and 3BNC117-LS on viral rebound dynamics following treatment interruption six months after dosing: four cases from the open label arm of the RIO trial

J. Frater, K. Seaton, M. Caskey, 2022, Journal of virus eradication.

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.

Allan C. deCamp, S. Hammer, J. Mascola, 2019, The Journal of clinical investigation.

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

Lindsay N. Carpp, Vicki C. Ashley, Allan C. deCamp, 2022 .

A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa

J. Kublin, M. McElrath, A. Fiore-Gartland, 2020, EClinicalMedicine.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

S. Hammer, B. Moss, D. Montefiori, 2014, The Journal of infectious diseases.

N-Myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef.

K. Seaton, Charles D. Smith, 2008, The Journal of general virology.

Vi-specific serological correlates of protection for typhoid fever

Rachel L. Spreng, Lindsay C. Dahora, B. Gunn, 2020, The Journal of experimental medicine.

AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.

D. Montefiori, S. Buchbinder, M. McElrath, 2021, Vaccine.

Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans

G. Pantaleo, M. McElrath, P. Gilbert, 2021, NPJ vaccines.

Immunological and Virological Mechanisms of Vaccine-Mediated Protection Against SIV and HIV

Mario Roederer, Raphael Gottardo, Gary J. Nabel, 2013, Nature.

Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials

Raphael Gottardo, Savita Pahwa, William Chad Young, 2021, Frontiers in Big Data.

Neurotensin receptor-1 inducible palmitoylation is required for efficient receptor-mediated mitogenic-signaling within structured membrane microdomains

R. Levenson, M. Kester, T. Fox, 2011, Cancer biology & therapy.

Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1

T. Hope, D. Montefiori, M. Tay, 2019, Journal of Virology.

Lower SARS-CoV-2–specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19

O. Hyrien, I. Frank, G. Tomaras, 2022, JCI insight.

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults

D. Montefiori, S. Buchbinder, N. Frahm, 2017, PloS one.

HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities

H. Liao, B. Haynes, M. McElrath, 2014, PloS one.

Methods for comparing durability of immune responses between vaccine regimens in early-phase trials

T. Westling, P. Gilbert, G. Tomaras, 2019, Statistical methods in medical research.

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein

Allan C. deCamp, J. Kublin, S. Omarjee, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine

B. Haynes, B. Moss, D. Montefiori, 2017, Journal of Virology.

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants

J. Andriesen, Yunda Huang, G. Tomaras, 2023, PLOS global public health.

Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination.

E. Jongert, M. Debois, G. Tomaras, 2020, Vaccine.

Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS

G. Tomaras, D. Barouch, N. Yates, 2021, Frontiers in Immunology.

Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.

A. Folgori, D. Montefiori, C. Labranche, 2016, Vaccine.

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

Allan C. deCamp, J. Mullins, J. Weiner, 2023, EBioMedicine.

Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

M. Nussenzweig, N. Pfeifer, S. Scholten, 2018, Nature Medicine.

Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

R. Bailer, P. Gilbert, J. Ledgerwood, 2017, mAbs.

Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01.

Lindsay N. Carpp, J. Mascola, D. Montefiori, 2019, Journal of Acquired Immune Deficiency Syndromes.

Rectal and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge

M. McElrath, A. McDermott, J. Ledgerwood, 2021 .

D. Montefiori, S. Buchbinder, N. Frahm, 2017, PloS one.

Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies

T. Kepler, S. Hammer, B. Haynes, 2015, Science.

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

Lindsay N. Carpp, Vicki C. Ashley, Allan C. deCamp, 2018, The Journal of infectious diseases.

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

Allan C. deCamp, J. Mullins, J. Weiner, 2023, EBioMedicine.

Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1

G. Fouda, G. Tomaras, D. Jamieson, 2015, Journal of Virology.